Schur, Nadine
Gudala, Kapil
Vudumula, Umakanth
Vadapalle, Sreelatha
Bhadhuri, Arjun http://orcid.org/0000-0003-1220-0731
Casanova, Alain
Adlard, Nicholas
Schwenkglenks, Matthias
Funding for this research was provided by:
Novartis
Universität Basel
Article History
Accepted: 17 March 2021
First Online: 1 April 2021
Declarations
:
: This study was funded by Novartis Pharma Schweiz AG, including research funding received by Matthias Schwenkglenks via Universität Basel. Open Access funding was provided by Universität Basel (Universitätsbibliothek Basel).
: Alain Casanova is an employee of Novartis Pharma Schweiz AG, Nicholas Adlard is an employee of Novartis Pharma AG, and Kapil Gudala, Umakanth Vudumula and Sreelatha Vadapalle are employees of Novartis Healthcare Private Limited. Matthias Schwenkglenks received research funding from Novartis Pharma Schweiz AG, via Universität Basel.
: No specific ethical approval was obtained for this study, as the present economic model did not involve the recruitment of human or animal subjects or the collection of research samples.
: Not applicable.
: Not applicable.
: A request for the Excel models can be made to the corresponding author but is not guaranteed because of copyright. Acceptance of the request is subject to approval from Novartis Pharma AG.
: Not applicable.
: AC, NS and MS conceptualised the study. KG, NA, and UV produced the underlying cost-effectiveness model. KG, NA and SV produced the underlying budget impact model. NS completed the cost-effectiveness adaptation and AB completed the budget impact adaptation. NS and AB drafted the manuscript. AC organised and led meetings with Swiss clinical experts, provided methodological guidance to estimate parameters and undertook primary research to estimate market shares in Switzerland. All authors contributed to interpreting the results and critically reviewed and edited the manuscript.